Programmed Death-Ligand 1 Monoclonal Antibody-Linked Immunoliposomes for Synergistic Efficacy of miR-130a and Oxaliplatin in Gastric Cancers

Abstract

<b>Aim:</b> PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes were constructed for enhanced therapeutic efficacy against gastric cancer. <b>Materials & methods</b>: The <i>in vitro</i> antitumor efficacy of the immunoliposomes was evaluated by cell viability, cell invasion, cell apoptosis and western blot analysis and <i>in vivo</i> antitumor efficacy was evaluated in a HGC27-bearing tumor xenograft model. <b>Results:</b> The inhibitory role of miR-130a was demonstrated in HGC27 cells by the downregulation of RAB5A and FOCL1 signaling pathways. Consequently, PD-miOXNP exhibited the strongest anticancer activity <i>in vitro</i> compared with any other formulation. PD-miOXNP showed a significantly higher anticancer efficacy in HGC27 tumors with reduced Ki67⁺ cells and increased TUNEL⁺ cells for mice group. <b>Conclusion:</b> PD-L1 monoclonal antibody-conjugated immunoliposomes have immense potential to be applied as a next-generation nanomedicine for PD-L1-positive gastric cancers.